Patents by Inventor Yueqing Hu

Yueqing Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triterpenoid compounds and methods of use thereof
    Patent number: 9029414
    Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.
    Type: Grant
    Filed: September 19, 2009
    Date of Patent: May 12, 2015
    Assignee: Biotechnology Research Corporation
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu
  • Receptor modulators exhibiting neuroprotective and memory enhancing activities
    Patent number: 8642567
    Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: February 4, 2014
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
  • Receptor modulators exhibiting neuroprotective and memory enhancing activities
    Patent number: 8637474
    Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: January 28, 2014
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
  • Isoquinolone compounds as subtype-selective agonists for melatonin receptors MTand MT
    Patent number: 8389544
    Abstract: A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor, R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl, substituted or unsubstituted aryl, NR9R10, or OR9; R9 is H, substituted or unsubstituted arylmethyl, or alkenyl; and R10 is H or alkyl.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: March 5, 2013
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Yung Hou Wong, Maurice Kwok Chung Ho, Yueqing Hu, David Charles New, Xixin He, Haihong Pang
  • RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES
    Publication number: 20130012462
    Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans.
    Type: Application
    Filed: January 5, 2012
    Publication date: January 10, 2013
    Applicant: Biotechnology Research Corporation Limited
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
  • TRITERPENOID COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20110288169
    Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.
    Type: Application
    Filed: September 19, 2009
    Publication date: November 24, 2011
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu
  • ISOQUINOLONE COMPOUNDS AS SUBTYPE-SELECTIVE AGONISTS FOR MELATONIN RECEPTORS MT1 AND MT2
    Publication number: 20100317691
    Abstract: A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor, R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl, substituted or unsubstituted aryl, NR9R10, or OR9; R9 is H, substituted or unsubstituted arylmethyl, or alkenyl; and R10 is H or alkyl.
    Type: Application
    Filed: January 17, 2007
    Publication date: December 16, 2010
    Inventors: Yung Hou Wong, Maurice Kwok Chung Ho, Yueqing Hu, David Charles New, Xixin He, Haihong Pang
  • RECEPTOR MODULATORS EXHIBITING NEUROPROTECTIVE AND MEMORY ENHANCING ACTIVITIES
    Publication number: 20100222286
    Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans.
    Type: Application
    Filed: November 10, 2009
    Publication date: September 2, 2010
    Applicant: The Hong Kong University of Science & Technology
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
  • Heterodimers and methods of using them
    Patent number: 7605265
    Abstract: Novel heterodimers of tetrahydroacridines and tetrahydroquinolinones are disclosed. The heterodimers are capable of acting as both acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. The heterodimers may be used to improve cognitive defects via treatment or prevention in both humans and non-humans.
    Type: Grant
    Filed: January 22, 2007
    Date of Patent: October 20, 2009
    Assignee: Biotechnology Research Corporation Ltd.
    Inventors: Nancy Y Ip, Fanny Chui Fun Ip, Yueqing Hu, Yifan Han, Sookja Kim Chung
  • Heterodimers and Methods of Using Them
    Publication number: 20080176308
    Abstract: Novel heterodimers of tetrahydroacridines and tetrahydroquinolinones are disclosed. The heterodimers are capable of acting as both acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. The heterodimers may be used to improve cognitive defects via treatment or prevention in both humans and non-humans.
    Type: Application
    Filed: January 22, 2007
    Publication date: July 24, 2008
    Applicant: BIOTECHNOLOGY RESEARCH CORPORATION LIMITED
    Inventors: Nancy Y. IP, Fanny Chui Fun IP, Yueqing Hu, Yifan Han, Sookja Kim Chung
  • Polycyclic guanine phosphodiesterase V inhibitors
    Patent number: 6969719
    Abstract: A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: November 29, 2005
    Assignee: Schering Corporation
    Inventors: Theodros Asberom, Yueqing Hu, Dmitri Pissarnitski, Ruo Xu, Yuguang Wang, Samuel Chackalamannil, John W. Clader, Andrew William Stamford
  • Polycyclic guanine derivative phosphodiesterase V inhibitors
    Patent number: 6943171
    Abstract: A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases:
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: September 13, 2005
    Assignee: Schering Corporation
    Inventors: Theodros Asberom, John W. Clader, Yueqing Hu, Dmitri A. Pissarnitski, Andrew W. Stamford, Ruo Xu
  • Polycyclic guanine derivative phosphodiesterase V inhibitors
    Publication number: 20050171129
    Abstract: A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases:
    Type: Application
    Filed: December 23, 2004
    Publication date: August 4, 2005
    Inventors: Theodros Asberom, John Clader, Yueqing Hu, Dmitri Pissarnitski, Andrew Stamford, Ruo Xu
  • Polycyclic guanine phosphodiesterase V inhibitors
    Publication number: 20030153587
    Abstract: A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.
    Type: Application
    Filed: August 26, 2002
    Publication date: August 14, 2003
    Applicant: Schering Corporation
    Inventors: Theodros Asberom, Yueqing Hu, Dmitri Pissarnitski, Ruo Xu, Yuguang Wang, Samuel Chackalamannil, John W. Clader, Andrew William Stamford